March 8, 2018
Authored and Edited by Samhitha Muralidhar Medatia; M. Andrew Holtman, Ph.D.
On February 28, 2018, FDA issued draft guidance on Standardization of Data and Documentation Practices for Product Tracing. FDA aims to provide trading partners information to appropriately track product information through the pharmaceutical distribution supply chain, in compliance with requirements that took effect in 2015 as part of section 582 of the Federal Food, Drug, and Cosmetic Act.
The draft guidance provides information on defining trading partners, standardizing data that trading partners should track, and appropriate documentation practices that satisfy statutory obligations.
FDA recognizes that an entity may meet the definition of more than one type of trading partner, depending on the activities it in which it engages. To be considered an authorized trading partner, an entity must have the applicable registrations and licenses for the type of activities it undertakes.
The draft guidance enumerates ten pieces of standardized “transaction information” that trading partners are required to track: (1) proprietary or established name; (2) strength and dosage form; (3) national drug code number; (4) container size; (5) number of containers; (6) lot number; (7) date of the transaction; (8) date of shipment; (9) business name and address of the person from whom ownership is being transferred; and (10) business name and address of the person to whom ownership is being transferred. Trading partners should also track the transaction history of products, either by compiling data from prior transactions or creating a single document with historical information.
Finally, FDA provides guidance on what documentation a trading partner should exchange when conducting specific types of transactions. This information generally includes the enumerated transaction information, transaction history, and transaction statement, as defined in the Federal Food, Drug, and Cosmetic Act. FDA further provides specific documentation guidance for drop shipments to dispensers and grandfathered products (those that entered the pharmaceutical supply chain before 2015).
Readers are encouraged to read the draft guidance, also available on FDA's website.
Food and Drug Administration (FDA), drugs, new drug application (NDA), Biologic License Application (BLA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.